Immuneering reports 17.3-month survival data for pancreatic cancer drug
Go back to Immuneering reports 17.3-month survival data for pancreatic cancer drug| ImaRx Therapeutics, Inc. (NASDAQ: IMRX) | Delayed: 4.44 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $4.44 | 52 Week High | $0.04 | |||
| Open | $4.44 | 52 Week Low | $0.00 | |||
| Day High | $4.44 | P/E | N/A | |||
| Day Low | $4.44 | EPS | $-0.09 | |||
| Volume | 1,722 | |||||
